Eterna Therapeutics Inc (ERNA)

$0.23 -0.02 (-6.24%)
Market Cap 1.43M
Revenue (ttm) 580,000.00
Net Income (ttm) -44.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,679.31%
Debt to Equity Ratio 0.00
Volume 359,085
Avg Vol 12,707,749
Day's Range N/A - N/A
Shares Out 5.41M
Stochastic %K 48%
Beta 4.47
Analysts Hold
Price Target N/A

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. Th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 798 6700
Address:
1035 Cambridge Street, Suite 18A, Cambridge, United States
Red2Profit
Red2Profit Jun. 19 at 1:51 PM
$ERNA Could we see a big move soon? Break 8.32 and let's see if we can get 15+. A good catalyst would help.
0 · Reply
HadesHODL
HadesHODL Jun. 18 at 8:20 PM
$ERNA $SOUN $MSFT $POET Loaded MLEC $
0 · Reply
Ernexatx
Ernexatx Jun. 17 at 1:13 PM
$ERNA Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/ernexa-therapeutics-positioned-to-become-a-clinical-stage-biotechnology-company-as-erna-101-on-track-for-planned-q3-2026-ind-submission-and-first-in-human-study.html
0 · Reply
2pumps1dump
2pumps1dump Jun. 17 at 1:11 PM
$ERNA sold that news quick 😒
0 · Reply
DekmarTrades
DekmarTrades Jun. 17 at 1:06 PM
List of Every Spike and Dump so Far this Morning in Order: 1. $EHGO 2. $CLWT 3. $NXTS 4. $ICCM 5. $ERNA Very Pump and Dump like morning. No Dip Buys!
1 · Reply
Olsen71
Olsen71 Jun. 17 at 1:02 PM
$ERNA 👍☺️
0 · Reply
focafoca99
focafoca99 Jun. 17 at 12:59 PM
$ERNA prepares for a Q3 2026 IND filing as it moves ERNA-101 into GMP manufacturing and first‑in‑human study planning.
0 · Reply
STACKD0E
STACKD0E Jun. 17 at 12:53 PM
$DSWL $ERNA $OCUL $RYET
1 · Reply
DARKP00L
DARKP00L Jun. 17 at 12:52 PM
$ERNA 08:47 on Jun. 17 2026 Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026 #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 17 at 12:47 PM
$ERNA Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
0 · Reply
Latest News on ERNA
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Jun 17, 2026, 8:47 AM EDT - 2 days ago

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Jun 9, 2026, 8:41 AM EDT - 10 days ago

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

2026-05-27T14:06:25.000Z - 23 days ago

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

May 27, 2026, 8:11 AM EDT - 23 days ago

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

May 20, 2026, 8:31 AM EDT - 4 weeks ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

May 11, 2026, 9:15 AM EDT - 5 weeks ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

Ernexa Therapeutics initiated with a Buy at Brookline

2026-05-07T21:58:10.000Z - 6 weeks ago

Ernexa Therapeutics initiated with a Buy at Brookline

3 Penny Stocks to Watch Now, 5/7/26

2026-05-07T16:17:11.000Z - 6 weeks ago

3 Penny Stocks to Watch Now, 5/7/26

AHMA PMAX

Ernexa Therapeutics announces new ERNA-101 preclinical data

2026-05-07T04:27:19.000Z - 6 weeks ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

May 6, 2026, 8:33 AM EDT - 6 weeks ago

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics announces 1-for-25 reverse stock split

2026-04-30T19:19:12.000Z - 7 weeks ago

Ernexa Therapeutics announces 1-for-25 reverse stock split

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Apr 30, 2026, 9:00 AM EDT - 7 weeks ago

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Mar 31, 2026, 8:55 AM EDT - 2 months ago

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Ernexa Therapeutics files $50M mixed securities shelf

2026-03-16T10:56:34.000Z - 3 months ago

Ernexa Therapeutics files $50M mixed securities shelf

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Feb 20, 2026, 9:05 AM EST - 4 months ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Ernexa Therapeutics prices 21M shares at 50c in public offering

2026-02-06T14:30:30.000Z - 4 months ago

Ernexa Therapeutics prices 21M shares at 50c in public offering

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 6, 2026, 9:25 AM EST - 4 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Feb 3, 2026, 8:45 AM EST - 4 months ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics files to sell common stock, warrants, no amount given

2026-02-03T11:21:14.000Z - 4 months ago

Ernexa Therapeutics files to sell common stock, warrants, no amount given

Ernexa selected as company for JETRO Japan entry acceleration program

2026-01-27T13:52:07.000Z - 5 months ago

Ernexa selected as company for JETRO Japan entry acceleration program

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Jan 27, 2026, 8:45 AM EST - 5 months ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics completes Pre-IND meeting with FDA

2026-01-06T13:38:50.000Z - 5 months ago

Ernexa Therapeutics completes Pre-IND meeting with FDA

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Jan 6, 2026, 8:15 AM EST - 5 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics presents preclinical data at ASH meeting on ERNA-101

2025-12-08T13:40:52.000Z - 6 months ago

Ernexa Therapeutics presents preclinical data at ASH meeting on ERNA-101

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 6 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 3, 2025, 8:30 AM EST - 7 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Ernexa Therapeutics appoints Ira Winer to Scientific, Medical Advisory Board

2025-12-02T13:55:30.000Z - 7 months ago

Ernexa Therapeutics appoints Ira Winer to Scientific, Medical Advisory Board

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Dec 2, 2025, 8:50 AM EST - 7 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 11, 2025, 7:00 AM EST - 7 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Ernexa Therapeutics reports Q3 operating loss $2M vs $2.3M last year

2025-11-10T13:40:53.000Z - 7 months ago

Ernexa Therapeutics reports Q3 operating loss $2M vs $2.3M last year

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 10, 2025, 8:35 AM EST - 7 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Nov 6, 2025, 9:15 AM EST - 8 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 29, 2025, 8:33 AM EDT - 8 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Oct 1, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 29, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 17, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 10, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Jun 10, 2025, 9:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 14, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Ernexa Therapeutics Closes New Funding Round

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Sep 5, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Red2Profit
Red2Profit Jun. 19 at 1:51 PM
$ERNA Could we see a big move soon? Break 8.32 and let's see if we can get 15+. A good catalyst would help.
0 · Reply
HadesHODL
HadesHODL Jun. 18 at 8:20 PM
$ERNA $SOUN $MSFT $POET Loaded MLEC $
0 · Reply
Ernexatx
Ernexatx Jun. 17 at 1:13 PM
$ERNA Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study https://www.globenewswire.com/news-release/2026/06/17/3313445/0/en/ernexa-therapeutics-positioned-to-become-a-clinical-stage-biotechnology-company-as-erna-101-on-track-for-planned-q3-2026-ind-submission-and-first-in-human-study.html
0 · Reply
2pumps1dump
2pumps1dump Jun. 17 at 1:11 PM
$ERNA sold that news quick 😒
0 · Reply
DekmarTrades
DekmarTrades Jun. 17 at 1:06 PM
List of Every Spike and Dump so Far this Morning in Order: 1. $EHGO 2. $CLWT 3. $NXTS 4. $ICCM 5. $ERNA Very Pump and Dump like morning. No Dip Buys!
1 · Reply
Olsen71
Olsen71 Jun. 17 at 1:02 PM
$ERNA 👍☺️
0 · Reply
focafoca99
focafoca99 Jun. 17 at 12:59 PM
$ERNA prepares for a Q3 2026 IND filing as it moves ERNA-101 into GMP manufacturing and first‑in‑human study planning.
0 · Reply
STACKD0E
STACKD0E Jun. 17 at 12:53 PM
$DSWL $ERNA $OCUL $RYET
1 · Reply
DARKP00L
DARKP00L Jun. 17 at 12:52 PM
$ERNA 08:47 on Jun. 17 2026 Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026 #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 17 at 12:47 PM
$ERNA Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
0 · Reply
CometaMan
CometaMan Jun. 15 at 10:42 AM
$ERNA Reminiscing the $10 s? 🤗
0 · Reply
CometaMan
CometaMan Jun. 15 at 9:18 AM
$ERNA Good morning, is this thing alive?
0 · Reply
OdinOmega
OdinOmega Jun. 13 at 12:22 PM
$ERNA
0 · Reply
TheBazaarTrades
TheBazaarTrades Jun. 13 at 12:39 AM
$BTX.X $ERNA Another RAVE 2.0. 🤣$RAVE.X
0 · Reply
CometaMan
CometaMan Jun. 12 at 9:00 PM
$ERNA started accumulating under 6.25
0 · Reply
breakeven2
breakeven2 Jun. 12 at 7:30 PM
$ERNA what the hack is this company doing? Come on Move the suck back above $10 this is unacceptable. 
0 · Reply
CometaMan
CometaMan Jun. 12 at 5:17 PM
$ERNA 🤑
0 · Reply
focafoca99
focafoca99 Jun. 9 at 1:17 PM
$ERNA explored its ERNA-101 ovarian cancer cell therapy in a virtual investor segment highlighting unmet need.
0 · Reply
VirtualInvestor
VirtualInvestor Jun. 9 at 1:17 PM
$ERNA In a #VirtualInvestor #KOLConnect segment, Dr. Ira Winer discusses the unmet need in ovarian cancer, the challenge of immunologically “cold” tumors and the potential of scalable, off-the-shelf engineered cell therapies. https://vimeo.com/1199557462/89d514b374?share=copy&fl=sv&fe=ci
0 · Reply
Ernexatx
Ernexatx Jun. 9 at 1:08 PM
$ERNA Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer https://bit.ly/4edgrnI
0 · Reply
CometaMan
CometaMan Jun. 4 at 2:30 PM
$ERNA Still waiting for $10. Will it happen today? 🤑 How about $CODX will it jump over $6 today. Those cheap shares under $5 are a steal!🤑 Stop flirting and let's get down to business! $SPRC nice ticker for day trading, love the spread! yum, yum!😋 $FOXX Did you get on the boat at $4 PM? AWESOME!!!! She is a foxie lady! 🦊
0 · Reply